Clinical trials: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS)
The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis
A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
- Trial name
- NCT07118319
- Testing
- Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Amyotrophic Lateral Sclerosis
Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis
Whether the mesenchymal injection on ALS patients is effective or not?
- Trial name
- NCT02116634
- Testing
- mesenchymal stem cell
- Where
- Iran
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alzahra Hospital, Iran
Paralysis; Quadriplegic, Quadraplegia
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer.
- Conditions
- Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
- Trial name
- NCT05936619
- Testing
- Mind Extender (MindEx)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nader Pouratian
Amyotrophic Lateral Sclerosis
Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to comprehensively investigate and analyze the home care needs and status quo of ALS patients in China, and to clarify their home care needs and status quo, so as to provide reference for the…
- Trial name
- NCT04953481
- Testing
- survey
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis
The purpose of this study is to determine the safety and tolerability of intramuscular injections of VM202 at different injection sites in people with amyotrophic lateral sclerosis.
- Trial name
- NCT02039401
- Testing
- VM202
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Helixmith Co., Ltd.
Familial Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
This study will test the safety, tolerability and pharmacokinetics of single doses of ISIS 333611 administered into the spinal canal as 12 hour infusions.
- Trial name
- SOD-1 (NCT01041222)
- Testing
- ISIS 333611
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis ALS7
The Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder that impairs motor neurons, with a life expectancy of 2 to 7 years after diagnosis.
- Trial name
- PEPINEX (NCT06249412)
- Testing
- MI-E with PEP function activated during the pause, MI-E without PEP function activated during the pause
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Groupe Hospitalier du Havre
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
IC14 for Treatment of Amyotrophic Lateral Sclerosis
Fifty patients with amyotrophic lateral sclerosis that is progressing rapidly will be randomized to receive either the monoclonal antibody IC14 or placebo to be given intravenously over two hours twice weekly for 12 weeks.
- Trial name
- NCT03508453
- Testing
- IC14
- Where
- Australia
- Sponsor
- Implicit Bioscience
ALS (Amyotrophic Lateral Sclerosis), Iron Overload
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
The FAIR-ALS study is to investigate the safety and efficacy of a scavenger treatment of iron deferiprone, which would reduce the brain iron to limit the development of amyotrophic lateral sclerosis.
- Trial name
- SAFEFAIRALS (NCT02164253)
- Testing
- Deferiprone
- Where
- France
- Volunteers
- 23 people
- Sponsor
- University Hospital, Lille
Amyotrophic Lateral Sclerosis
A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS
This is an open-label, follow-on phase 1 study to assess the long-term safety and tolerability of continuous i.c.v administration of 4 μg sNN0029/day in patients with ALS who previously participated in study sNN0029-003
- Trial name
- NCT02269436
- Testing
- sNN0029 infusion solution
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 11 people
- Sponsor
- Newron Sweden AB
Amyotrophic Lateral Sclerosis, ALS
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive…
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03537807
- Testing
- Riluzole
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis
Digital Assessment of Speech and Fine Motor Control in ALS
This is a single-session, case-control study that incorporates digital tools for assessing speech and motor function in motor neuron disease.
- Conditions
- Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
- Trial name
- NCT06315673
- Testing
- Digital Speech and Handwriting Assessment
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Anarthria, Dysarthria
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with…
- Conditions
- Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries
- Trial name
- BG-Speech-01 (NCT05724173)
- Testing
- BrainGate Neural Interface System
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Amyotrophic Lateral Sclerosis
Triumeq in Amyotrophic Lateral Sclerosis
To determine if Triumeq improves survival in Amyotrophic Lateral Sclerosis (ALS) compared with placebo
- Trial name
- LIGHTHOUSE II (NCT05193994)
- Testing
- Dolutegravir, Abacavir and Lamivudine
- Where
- 28 sites in Australia, Ireland and 6 more
- Volunteers
- 419 people
- Sponsor
- Macquarie University, Australia
Multiple Sclerosis, Amyotrophic Lateral Sclerosis
Polish Version Fatigue Severity Scale
Fatigue is one of main symptoms in multiple sclerosis, amyotrophic lateral sclerosis and other diseases with profound effect on quality of life and professional and social functioning.
- Conditions
- Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stroke, Ischemic
- Trial name
- NCT06668649
- Testing
- Testing with Questionnaires
- Where
- 2 sites in Poland
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Jakub Antczak
Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders
The hypothesis is that a mechanical insufflation-exsufflation (MI-E) is associated with a decrease in the number of intubations and more rapid clinical improvement in children and adults with neuromuscular disease who are…
- Conditions
- Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Neuromuscular Diseases
- Trial name
- Nemucough (NCT00839033)
- Testing
- mechanical insufflation - exsufflation, Standard respiratory physiotherapy
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis, Muscular Dystrophy
Innovative Ultrasound Technology in Neuromuscular Disease
This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine…
- Conditions
- Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Radiculopathy, Myopathy
- Trial name
- AQUIRe (NCT02104921)
- Where
- United States
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Motor Neuron Disease
A Study of Monepantel in Individuals With Motor Neurone Disease
Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden.
- Trial name
- NCT04894240
- Testing
- Monepantel
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Neurizon Therapeutics Limited
Amyotrophic Lateral Sclerosis
Appetite and Related Factors in Patients With ALS
Chinese cnaq scale was used to evaluate the appetite changes of Chinese ALS patients; Objective to investigate the related factors of appetite changes in ALS patients; Objective to investigate the effect of anorexia on the…
- Trial name
- NCT04953624
- Testing
- Appetite rating scale CNAQ
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT00875446
- Testing
- GSK1223249
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 76 people
- Sponsor
- GlaxoSmithKline